Main products
Cerebral Torque
(Save $8.00)
Wed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read MoreSat, Apr 19, 25
FDA Authorizes First Digital Therapeutic for Migraine
In a development for migraine patients, the FDA has granted marketing authorization to CT-132, making it the first prescription digital therapeutic specifically designed for the preventive treatment of episodic migraine...
Read More